Phase 3 N=149 Alkali Therapy in Chronic Kidney Disease
Chronic Kidney Disease · Metabolic Acidosis
Primary: Sit to Stand to Sit Speed: Time Taken to Sit to Stand to Sit 10 Times — 23.8; 22.9 seconds
Clinical Trial Search
Completed trials with posted results — search by concept, filter by the parameters that matter at the bedside.
N/A N=20 Metabolic Acidosis and Vascular Function in Patients With Chronic Kidney Disease
Metabolic Acidosis · Chronic Kidney Disease
Primary: Change in Brachial Artery Flow Mediated Dilation (FMD) — 1.1; -0.7 absolute change in percent FMD
N/A N=11 Acid-Base Composition With Use of hemoDialysates
End Stage Renal Disease
Primary: Peridialytic Arterialized Blood Bicarbonate Concentrations — 25.7; 27.1; 27.2; 27.4 mEq/l — p=<0.0001
Phase 2 N=50 Bicarbonate in Patients With Out-of-hospital Cardiac Arrest
Cardiac Arrest · Metabolic Acidosis
Primary: Return of Spontaneous Circulation (ROSC) — 4; 16 ROSC percents of each group
Phase 3 N=217 Evaluation of TRC101 in Subjects With Metabolic Acidosis Associated With Chronic Kidney Disease
Metabolic Acidosis
Primary: Subjects With Change From Baseline in Serum Bicarbonate of ≥ 4 mEq/L or Serum Bicarbonate Within the Normal Range — 59.2; 22.5; 55.8; 21.3 percentage of participants…
N/A N=83 Dietary Acid Load, Kidney Function and Disability in Elderly
Chronic Kidney Disease · Disability
Primary: Blood Bicarbonate — 22.8; 23.2 mmol/L
N/A N=171 Effect of Potassium Bicarbonate Supplementation on Bone and Muscle in Older Adults
Osteoporosis · Sarcopenia
Primary: Biochemical Markers of Bone Turnover — -6.25; -3.36; -0.14; 0.5 nmol/mmol
N/A N=12 Lactic Acidosis During and After Seizures
Epilepsy
Primary: Salivary Lactic Acid Levels With Seizures — 8.16 mmol/L
Phase 3 N=59 Impact of Intraoperative Fluid Management on Electrolyte and Acid-base Variables
Anesthesia
Primary: Change in Base Deficit — -1.5; -1.2; -0.5 mEq/L
Phase 2 N=244 Musculoskeletal Effects of Bicarbonate
Muscle Loss · Fractures · Osteoporosis, Age Related
Primary: The Dose of Potassium Bicarbonate Needed for Maximal Suppression of 24-hr Urinary N-telopeptide — 240; 230; 241; -53 nmol/day
Early Phase 1 N=34 Bicarbonate Administration and Cognitive Function in Midlife and Older Adults With CKD
Metabolic Acidosis · Chronic Kidney Disease · Cognitive Dysfunction
Primary: Change in Cognitive Function Composite Score at 12 Months — 52.3; 47.3; 53.5; 49.3 T-score
N/A N=109 Bicarbonate Administration in CKD
Chronic Kidney Disease · Metabolic Acidosis
Primary: Change in Brachial Artery Flow Mediated Dilation — 3.99; 3.78; 4.25; 4.43 percentage
Phase 3 N=10 Chronic Versus Acute Dosing of Sodium Citrate for Swimming 200m
Alkalosis
Primary: Time — 144.2; 145.3; 145.3; 144.8 seconds
Phase 2 N=135 Evaluation of TRC101 in Subjects With Chronic Kidney Disease and Metabolic Acidosis
Acidosis
Primary: Number of Subjects With Treatment Emergent Adverse Events (TEAEs) and Number of Subjects Who Discontinued Study Drug Due to a TEAE — 14; 13; 9; 17 Participants
Phase 1 N=105 Duration of Effect of Acidform Gel on Vaginal pH
Healthy
Primary: Change in Vaginal pH Following a Single Dose of Acidform (3, 4, and 5 g), HEC Placebo (4 g), or no Intervention. — 4.85; 4.81; 4.91; 5.00 pH